Terms: = Bone cancer AND FIP1L1, DKFZp586K0717, 81608, ENSG00000145216, Q6UN15 AND Treatment
14 results:
1. fip1l1-PDGFRA fusion gene in T-lymphoblastic lymphoma: A case report.
Ali S; Al-Qattan Y; Awny W; Hamadah A; Pinto K; AlShemmari S
Cancer Rep (Hoboken); 2023 Jan; 6(1):e1769. PubMed ID: 36517458
[TBL] [Abstract] [Full Text] [Related]
2. LCP1 triggers mTORC2/AKT activity and is pharmacologically targeted by enzastaurin in hypereosinophilia.
Ma G; Gezer D; Herrmann O; Feldberg K; Schemionek M; Jawhar M; Reiter A; Brümmendorf TH; Koschmieder S; Chatain N
Mol Carcinog; 2020 Jan; 59(1):87-103. PubMed ID: 31691359
[TBL] [Abstract] [Full Text] [Related]
3. Identification of a novel PDGFRA point mutation at p.P6L as a potential molecular target of imatinib in an eosinophilia patient showing genetic heterogeneity.
Zhao M; Wu Q; Xia L; Zhang M; Yang J; Li Y; Tu S; Wang Y
Cancer Biol Ther; 2019; 20(4):402-407. PubMed ID: 30359545
[TBL] [Abstract] [Full Text] [Related]
4. Coexisting of bone marrow fibrosis, dysplasia and an X chromosomal abnormality in chronic neutrophilic leukemia with CSF3R mutation: a case report and literature review.
Wu XB; Wu WW; Zhou Y; Wang X; Li J; Yu Y
BMC Cancer; 2018 Mar; 18(1):343. PubMed ID: 29587671
[TBL] [Abstract] [Full Text] [Related]
5. Imatinib for the treatment of hypereosinophilic syndromes.
Helbig G
Expert Rev Clin Immunol; 2018 Feb; 14(2):163-170. PubMed ID: 29303368
[TBL] [Abstract] [Full Text] [Related]
6. WATERSHED INFARCTION IN HYPEREOSINOPHILIC SYNDROME: A DIAGNOSTIC DILEMMA IN fip1l1-PDGFR ALPHA-ASSOCIATED MYELOID NEOPLASM.
Marton I; Pósfai É; Annus JK; Borbényi Z; Nemes A; Vecsei L; Vörös E
Ideggyogy Sz; 2015 May; 68(5-6):212-6. PubMed ID: 26182612
[TBL] [Abstract] [Full Text] [Related]
7. Discovery of imatinib-responsive fip1l1-PDGFRA mutation during refractory acute myeloid leukemia transformation of chronic myelomonocytic leukemia.
Shah S; Loghavi S; Garcia-Manero G; Khoury JD
J Hematol Oncol; 2014 Mar; 7():26. PubMed ID: 24669761
[TBL] [Abstract] [Full Text] [Related]
8. Hes1 upregulation contributes to the development of fip1l1-PDGRA-positive leukemia in blast crisis.
Uchida T; Kitaura J; Nakahara F; Togami K; Inoue D; Maehara A; Nishimura K; Kawabata KC; Doki N; Kakihana K; Yoshioka K; Izawa K; Oki T; Sada A; Harada Y; Ohashi K; Katayama Y; Matsui T; Harada H; Kitamura T
Exp Hematol; 2014 May; 42(5):369-379.e3. PubMed ID: 24486648
[TBL] [Abstract] [Full Text] [Related]
9. A case of nonleukemic myeloid sarcoma with fip1l1-PDGFRA rearrangement: an unusual presentation of a rare disease.
Chen D; Bachanova V; Ketterling RP; Begna KH; Hanson CA; Viswanatha DS
Am J Surg Pathol; 2013 Jan; 37(1):147-51. PubMed ID: 23232855
[TBL] [Abstract] [Full Text] [Related]
10. Pathogenesis, classification, and therapy of eosinophilia and eosinophil disorders.
Valent P
Blood Rev; 2009 Jul; 23(4):157-65. PubMed ID: 19246139
[TBL] [Abstract] [Full Text] [Related]
11. Imatinib: new indication. New indications, but not robust evidence.
Prescrire Int; 2008 Jun; 17(95):91-4. PubMed ID: 18623899
[TBL] [Abstract] [Full Text] [Related]
12. PDGFRalpha/fip1l1-positive chronic eosinophilic leukemia presenting with retro-orbital localization: efficacy of imatinib treatment.
Vigna E; Lucia E; Gentile M; Mazzone C; Bisconte MG; Gentile C; Armentano A; Ottaviani E; Rondoni M; Martinelli G; Morabito F
Cancer Chemother Pharmacol; 2008 Apr; 61(4):713-6. PubMed ID: 17549478
[TBL] [Abstract] [Full Text] [Related]
13. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial.
Droogendijk HJ; Kluin-Nelemans HJ; van Doormaal JJ; Oranje AP; van de Loosdrecht AA; van Daele PL
Cancer; 2006 Jul; 107(2):345-51. PubMed ID: 16779792
[TBL] [Abstract] [Full Text] [Related]
14. PKC412 overcomes resistance to imatinib in a murine model of fip1l1-PDGFRα-induced myeloproliferative disease.
Cools J; Stover EH; Boulton CL; Gotlib J; Legare RD; Amaral SM; Curley DP; Duclos N; Rowan R; Kutok JL; Lee BH; Williams IR; Coutre SE; Stone RM; DeAngelo DJ; Marynen P; Manley PW; Meyer T; Fabbro D; Neuberg D; Weisberg E; Griffin JD; Gilliland DG
Cancer Cell; 2003 May; 3(5):459-69. PubMed ID: 12781364
[TBL] [Abstract] [Full Text] [Related]
